eftilagimod alpha,pembrolizumab
Immutep,Merck
['thanks', 'tacti-002', 'immutep']
 we are pleased to share compelling data from tacti-002 phase ii trial in 1st line #nsclc at #sitc2022. a special thanks to dr. iams for his oral presentation of our late-breaking abstract (#1470). join our webcast today to learn more: 